Jason M Pogue, PharmD, BCPS, BCIDP discusses the findings, pharmacokinetics, why ceftolozane-tazobactam may be the preferred choice for resistant infections, and more.
Investigators propose limiting initial use of antibiotics for group A streptococcal pharyngitis in children after finding placebo noninferior in reducing symptoms.
The Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing had its series of meetings to update breakpoints for a variety of classes of antimicrobials.
At ID Week 2024, in a late-breaking presentation, investigators are reporting it is safe to cut the antibiotic regimen in half without endangering patients for these infections.